Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review.

ABSTRACT: The term severe mental illness (SMI) encompasses those psychiatric disorders exerting the highest clinical burden and socio-economic impact on the affected individuals and their communities. Pharmacogenomic (PGx) approaches hold great promise in personalizing treatment selection and clinical outcomes, possibly reducing the burden of SMI. Here, we sought to review the literature in the field, focusing on PGx testing and particularly on pharmacokinetic markers. We performed a systematic review on PUBMED/Medline, Web of Science, and Scopus. The last search was performed on the 17 September 2022, and further augmented with a comprehensive pearl-growing strategy. In total, 1979 records were screened, and after duplicate removal, 587 unique records were screened by at least 2 independent reviewe

SUBMITTER: Paribello P 

PROVIDER: S-EPMC10003720 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature